506 filings
Page 5 of 26
8-K
g9efm2 52
28 Feb 22
Minerva Neurosciences Announces Publication of Roluperidone Phase 3 Study Results in Schizophrenia Bulletin
9:17am
4
w3bja3j
18 Feb 22
Minerva Neurosciences / Frederick W Ahlholm ownership change
4:36pm
4
jin6 ljl2wv
18 Feb 22
Minerva Neurosciences / Geoff Race ownership change
4:34pm
4
9frq4hg9p
18 Feb 22
Minerva Neurosciences / Remy Luthringer ownership change
4:33pm
SC 13G/A
waej3v8m 9nq
14 Feb 22
Minerva Neurosciences / FEDERATED HERMES ownership change
1:53pm
SC 13G/A
oj75f9dcvpmj28p
11 Feb 22
Minerva Neurosciences / Luthringer Remy ownership change
9:06am
SC 13G/A
unqs pmkm
10 Feb 22
Minerva Neurosciences / VANGUARD ownership change
12:00am
8-K
2xkq4vgu
18 Jan 22
Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard
9:16am
8-K
3w73sl9854lot xq
5 Jan 22
Regulation FD Disclosure
8:15am
8-K
acubfrfilgzujh8q
8 Dec 21
Regulation FD Disclosure
4:06pm
4
gr2idiet omev4
3 Dec 21
Minerva Neurosciences / David Kupfer ownership change
5:37pm
SC 13G
ts26sa2k
24 Nov 21
Minerva Neurosciences / Assenagon Asset Management ownership change
9:13am
SC 13G
irtpfd9o
24 Nov 21
Minerva Neurosciences / Assenagon Asset Management ownership change
9:11am
8-K
r7f3sl
3 Nov 21
Other Events
8:51am
8-K
obu82y5mkf
12 Oct 21
Minerva Neurosciences Announces Promotion of Geoff Race to President
6:08am
8-K
tyc1ce yre9mt
30 Sep 21
Company to Request Pre-NDA Meeting with U.S. Food and Drug Administration
8:53am
8-K
14tcpx40ox74 xroi
8 Sep 21
Minerva Neurosciences Announces Appointment of
8:42am
SC TO-I/A
4psdy5jsd8sqz7p
9 Aug 21
Issuer tender offer statement (amended)
8:19am